Releases
ATNF
2.330
+15.92%
0.320
  • All
  • Financials
  • Insiders
More
Webull provides the latest 180 Life Sciences Corp (ATNF) stock and general news. This information may help you make smarter investment decisions.
About ATNF
180 Life Sciences Corp. is a clinical-stage biotechnology company. The Company is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing research, and combination therapy. The Company's focus is a program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms Anti-TNF platform, SCAs platform and a7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The a7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is also undertaking preclinical research and development activities for the SCA and the a7nAChR platforms.